ARCA Biopharma (ABIO.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.14, previous value of -$0.09.

ARCA Biopharma (ABIO.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.14, previous value of -$0.09.

Zhitong FinanceApr 26 05:50

ARCA Biopharma Q1 EPS $(0.14) Down From $(0.09) YoY

ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.14) per share. This is a 55.56 percent decrease over losses of $(0.09) per share from the same period last year.

BenzingaApr 26 04:48

ARCA Biopharma 1Q Loss/Shr 14c >ABIO

ARCA Biopharma 1Q Loss/Shr 14c >ABIO

Dow JonesApr 26 04:15

Press Release: ARCA Biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update -- ARCA biopharma and Oruka Therapeutics announce Merger Agreement -- ARCA biopharma appoints Thomas

Dow JonesApr 26 04:15

Arca Biopharma Increases Executive Retention Bonuses

TipRanksApr 24 04:32

ARCA Biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024

ARCA Biopharma 13D Filing Shows Adage Capital Management, L.P. Reported A 8.28% Stake In The Co As Of April 3, 2024

BenzingaApr 6 04:17